iccm stock guide

This guide explains iccm stock — IceCure Medical Ltd. listed on NASDAQ — covering company overview, products, clinical and regulatory context, markets, financial and stock facts, risks, competitors...

2024-07-10 02:43:00

By Crypto Linguist

Article rating

4.7

117 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

IceCure Medical Ltd. (ICCM)

IceCure Medical Ltd. (ICCM) is an Israeli commercial-stage medical device company focused on cryoablation systems to treat solid tumors and certain benign lesions. This article explains the business and technology, clinical evidence and regulatory context, markets and commercialization, financial and stock information, governance and risks, and practical next steps for investors and clinicians who want reliable sources to track ICCM stock and company developments.

As a reminder: this is an informational overview, not investment advice. All market figures and regulatory statuses change frequently — verify the latest figures on official company investor relations pages, NASDAQ market pages, and recent SEC or company filings. As of 2026-01-27, according to company investor relations and major market-data providers, IceCure is an issuer trading under the ticker ICCM on the NASDAQ Capital Market; live market data such as market capitalization and daily volume require checking real-time quotes.

Company overview

IceCure Medical develops and commercializes liquid-nitrogen-based cryoablation systems for minimally invasive treatment of tumors and select benign conditions. The company aims to offer interventional clinicians a set of devices intended for outpatient or minimally invasive procedures performed by radiologists, surgeons, and other specialists.

Primary product families historically communicated by the company include ProSense, IceSense3, XSense, and MultiSense platforms. These systems use liquid nitrogen to create a cold zone at the cryoprobe tip, causing targeted tissue freezing (cryoablation) to destroy diseased tissue. Clinical indications targeted in public materials include small breast tumors, lung nodules, kidney lesions, gynecological and dermatological indications, and certain soft-tissue masses.

IceCure’s business model combines direct sales in some markets with distributor relationships in others and revenue streams from device sales, consumable cryoprobes, and procedure-related disposables. The company positions its technology as a less invasive alternative to surgical excision for select patients, with potential benefits including shorter procedure times, reduced recovery, and the possibility of outpatient care.

History

Founding and early development

IceCure Medical was founded in the mid-2000s to develop cryoablation technology leveraging liquid-nitrogen cooling. Early years focused on device engineering, animal studies, and initial human feasibility work to test safety and ablative effectiveness. The company moved from R&D toward clinical pilot programs and initial commercialization in select markets.

Public listing and corporate milestones

IceCure later pursued a public listing to access capital for clinical development and commercialization. The company’s securities trade on the NASDAQ Capital Market under the ticker ICCM. Since listing, IceCure has announced successive commercial rollouts, clinical presentations, and regulatory interactions intended to expand indications and geographic reach. As with any small-cap medical device company, milestones have typically included regulatory submissions, investigator-initiated and company-sponsored studies, commercial agreements, and capital-raising events. For the latest milestone chronology and filings, consult the company investor relations materials and SEC or exchange disclosures.

Products and technology

IceCure’s product portfolio centers on cryoablation systems and single-use or reusable cryoprobes. The platforms commonly referenced are:

ProSense: A cryoablation system intended for targeted tumor ablation with single-use probes for various lesion sizes.
IceSense3: A compact cryoablation generator and probe family optimized for office-based or interventional radiology procedures.
XSense and MultiSense: Probe and system variants designed for different clinical settings and lesion geometries.

How liquid-nitrogen cryoablation works (brief, non-technical):

A thin cryoprobe is placed within or adjacent to the target tissue under image guidance (ultrasound, CT, or fluoroscopy).
Liquid nitrogen flows to the probe tip, rapidly freezing adjacent tissue and forming an expanding iceball that encompasses the tumor.
A controlled freeze–thaw cycle damages cell membranes and microvasculature, resulting in tissue necrosis.
After a monitored freeze cycle, the probe is removed and the treated area heals over time.

Clinical benefits promoted for cryoablation compared with more invasive surgical alternatives include preservation of surrounding tissue, reduced scarring, shorter recovery, possible outpatient treatment, and potential for better cosmetic outcomes in appropriate cases. The degree of benefit depends on lesion size, location, and operator experience.

Clinical evidence and regulatory status

IceCure has presented clinical data and participated in peer-reviewed publications and medical meetings describing outcomes after cryoablation in specific indications. Clinical evidence typically addresses safety endpoints (procedure-related complications, adverse events) and efficacy surrogates (local tumor control, need for re-intervention, recurrence rates) over defined follow-up intervals.

Regulatory pathways for cryoablation devices vary by jurisdiction. In the United States, relevant pathways include FDA device clearance or approval routes; in Europe, CE marking and local regulatory compliance apply; in other markets like Japan, specific regulatory submissions are required. Regulatory statuses can evolve as new indications are pursued or as additional clinical evidence is submitted.

As of 2026-01-27, according to company investor relations and major market-data providers, IceCure has ongoing clinical activity and regulatory interactions; the precise clearance or approval status for each device and indication should be confirmed through the company's public filings and statements. Regulatory status changes frequently and should be verified against primary sources such as company announcements and regulatory authority databases.

Markets and commercialization

IceCure targets several geographic markets with different commercialization strategies:

United States: a major target market where commercialization often requires FDA interaction and physician adoption through clinical evidence and training programs.
Europe and other international markets: distribution via local partners or direct sales where regulatory frameworks permit.
Select APAC markets: targeted commercialization through partners or local regulatory approvals.

Sales channels vary: direct sales to hospitals and clinics in some countries; distributor partnerships in others. Typical clinical customers are hospitals, outpatient surgical centers, and interventional radiology practices. Adoption requires physician training, imaging support, and procedural reimbursement considerations; reimbursement policies differ by country and by payer.

Financial overview

Investors who follow ICCM stock and similar small-cap medical device issuers commonly track several financial metrics:

Market capitalization: total value derived from share price × outstanding shares. This figure varies daily with market price.
Revenue trends: device sales, recurring revenue from consumables, and service/maintenance contracts.
Profitability: net income or loss, earnings per share (EPS) and operating margin.
Cash position and debt: cash on hand, short- and long-term debt, and runway relative to operating burn.
Financing: equity raises, debt financings, ATM or shelf registrations, and convertible instruments.
Key ratios: current ratio, quick ratio, and other liquidity or leverage measures.

All numerical financial details change over time; verify the latest figures by checking the company’s quarterly and annual filings and reputable market-data providers.

Recent financial performance

As of 2026-01-27, according to company investor relations and commonly referenced market-data pages, IceCure’s revenue and profitability have reflected the early commercial rollouts typical of medical device companies transitioning from pilot-stage sales to broader commercialization. Small-cap medtech companies often report periods of investment-driven operating losses while building commercial infrastructure. For up-to-date quarterly results, financing announcements, or shelf registrations, consult the company’s most recent filings and press releases.

Stock information

Ticker symbol and exchange: ICCM on the NASDAQ Capital Market.
Share class: the company’s common shares trade under the ICCM ticker; confirm share-class details and any outstanding preferred or convertible securities in the company’s filings.
Trading characteristics: ICCM stock has historically presented typical small-cap characteristics — lower average trading volume relative to large-cap names and potential for elevated price volatility. Specific volume and volatility metrics should be checked in real time.

Historical price performance

Historical price behavior for ICCM stock has included periods of significant movement correlated with company announcements, clinical data releases, and broader market sentiment toward small-cap healthcare names. For precise historical high/low ranges and the 52-week range, review market data providers or the exchange quote pages.

Analyst coverage and sentiment

Coverage by sell-side analysts and independent research firms for small-cap medtech firms can be limited. Where coverage exists, analyst notes may provide revenue forecasts, price targets, and risk assessments. These estimates vary across firms and should be treated as opinions rather than facts. Institutional investor filings and sell-side reports — when available — offer additional context but are not a substitute for primary company filings.

Corporate governance

IceCure’s governance structure includes an executive management team (CEO and senior officers) and a board of directors. The company is headquartered in Israel with international commercial and clinical activities. For up-to-date names, biographies of key executives and board members, and the number of employees, consult the company’s investor relations disclosures and annual reports.

Ownership and major shareholders

Ownership structure for ICCM stock typically includes a mix of institutional investors, insider holdings (executive officers and directors), and retail shareholders. Institutional ownership and insider holdings can materially influence liquidity and potential voting outcomes. Public filings (such as Form 13D/G in the U.S. or the company’s proxy/annual disclosures) provide verified lists of major shareholders and changes in ownership positions.

Risks and controversies

Potential risks relevant to ICCM stock and to companies in the cryoablation/medical device sector include:

Regulatory approval risk: devices and new indications require regulatory review; unfavorable outcomes or delays can materially affect commercialization plans.
Clinical outcome risk: clinical trials and real-world performance must demonstrate safety and efficacy; adverse events or poor efficacy can limit adoption.
Commercial adoption risk: uptake depends on physician training, reimbursement, competition, and institutional purchasing decisions.
Competitive risk: other thermal and non-thermal ablation technologies compete for the same clinical use cases.
Financing and dilution risk: small-cap companies frequently raise capital which can dilute existing shareholders.
Operational risk: manufacturing, supply-chain disruptions, and quality-control issues can affect product availability.

Any disclosed litigation, regulatory investigation, or material operational incident should be verified in company filings and regulatory announcements.

Competitors and industry context

IceCure operates within the broader minimally invasive oncology-treatment and interventional-device landscape. Competitors comprise companies developing cryoablation systems as well as makers of radiofrequency ablation, microwave ablation, and other thermal or non-thermal tumor-ablation technologies. Competitive positioning depends on factors such as device performance, procedure time, probe versatility, device footprint, physician preference, and reimbursement pathways.

The global ablation market continues to evolve as devices aim to expand outpatient oncology care and provide alternatives to surgery for select early-stage tumors and palliative applications.

Recent developments (selected)

As of 2026-01-27, according to company investor relations and major market-data providers, IceCure continues to report commercial activity, clinical presentations, and regulatory interactions; check the company’s press releases and filings for up-to-date announcements and precise dates.
Industry conferences and peer-reviewed publications periodically report clinical outcomes for cryoablation procedures; these presentations can influence clinician adoption and referral patterns.
Financing activity: small-cap medical device companies intermittently announce financings (equity, debt, or registered shelf offerings). For any announced capital raises or shelf filings, verify details and effective dates in the corresponding company filings.

For the latest, verifiable updates, consult primary sources such as the company’s investor relations releases and regulatory filings.

References and further reading

This article is intended as a structured overview. For primary verification and the most recent, quantifiable data on ICCM stock and IceCure Medical, consult:

Company investor relations materials and press releases.
SEC filings and exchange disclosures for U.S.-listed companies.
Market-data providers and real-time exchange quotes for live price, market cap, and volume data.
Peer-reviewed clinical journals and conference proceedings for study data and methodologies.

As of 2026-01-27, according to public market-data providers and the company’s IR page, details such as market capitalization, average daily trading volume, and the status of regulatory submissions should be confirmed from these primary sources before making any business or financial decisions.

External links

Note: External links and direct URLs are intentionally omitted from this article. To access primary resources, search for IceCure Medical investor relations, ICCM NASDAQ quote pages, and peer-reviewed clinical publications by the company name and device family.